T7473

5-bromoindole is a potential inhibitor of glycogen synthase kinase 3 (GSK-3)and an important pharmaceutical chemical intermediate

SPC4061, a potent PCSK9 inhibitor and an antisense nucleotide, specifically targets the lock-in nucleic acid (LNA) of PCSK9. This action is relevant for researching hypercholesterolemia and associated diseases [1] [2].

L18-MDP, a derivative of the antibacterial agent muramyl dipeptide, exhibits antibacterial activity and shows promise for use in treating bacterial and fungal infections [1].

PROTAC PTPN2 Degrader-1 (compound example 77) is a potent entity capable of degrading PTPN2, showing promise for research applications in cancer or metabolic diseases [1].

OSM-SMI-10B, a derivative of OSM-SMI-10, effectively inhibits Oncostatin M (OSM)-induced STAT3 phosphorylation in cancer cells when co-incubated with OSM [1].

Gly-Cyclopropane-Exatecan, a DNA Topoisomerase I inhibitor containing Exatecan, is key in synthesizing the anti-B7-H4 ADC, specifically the ADC hu2F7-Exatecan (compound 34). This compound demonstrated antitumor activity both in vivo and in vitro [1].

Mono-Pal-MTO, a palm oil-derived lipid formed by integrating the anticancer agent mitoxantrone (MTO) with palmitoleic acid, exhibits enhanced anticancer activity and efficient siRNA cell delivery when its nanoparticles are mixed with those of di-Pal-MTO at a molar ratio of 1:1 [1].

Di-Pal-MTO, a lipid derivative synthesized from palm oil by integrating the anticancer agent mitoxantrone (MTO) with palmitoleic acid, exhibits enhanced anticancer activity and efficient siRNA cell delivery when nanoparticles of mono-Pal-MTO and di-Pal-MTO are combined at a molar ratio of 1:1 [1].

Oleoyl-D-lysine, a lipid-based selective Glycine Transporter-2 (GlyT2) inhibitor, effectively reverses neuropathic pain and exhibits an antidrowsiness effect in mice with chronic neuropathic pain. It is considered safe and efficacious, without causing respiratory depression [1].